循环肿瘤DNA
生物标志物
微小残留病
循环肿瘤细胞
疾病
DNA
生殖细胞肿瘤
癌症研究
残余物
医学
肿瘤科
病理
临床试验
内科学
癌症
前瞻性队列研究
免疫疗法
疾病监测
生殖系
实体瘤
恶性疾病
进行性疾病
液体活检
作者
Rebecca Hassoun,Reuben Ben‐David,John P. Sfakianos,George Laliotis,Cherry Au,Clint Cary,Timothy A. Masterson,Kevin I. Manage,Punashi Dutta,Neeraja Tillu,Shivaram Cumarasamy,Jennifer M. King,Jordan Miller Rich,Adam G. Rock,Tanya Barauskas Dorff,Mukti Patel,Shruti Sharma,Adam C. ElNaggar,MC Liu,Alan Tan
出处
期刊:JCO precision oncology
[Lippincott Williams & Wilkins]
日期:2025-09-24
卷期号:9 (9): e2500176-e2500176
被引量:12
摘要
PURPOSE Serum tumor markers (STMs), including alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG), are currently used in management of patients with germ cell tumors (GCTs). STMs in a substantial proportion of patients are normal or falsely elevated. We evaluated circulating tumor DNA (ctDNA) as a prognostic biomarker in patients with GCTs. PATIENTS AND METHODS Longitudinal ctDNA testing was performed on a multi-institutional cohort of patients with GCTs using a clinically validated, personalized, tumor-informed 16-plex multiplex PCR-NGS ctDNA assay (Signatera, Natera Inc). ctDNA was evaluated preorchiectomy and during the molecular residual disease (MRD; 1-12 weeks postorchiectomy) and surveillance windows (>12 weeks postorchiectomy, after retroperitoneal lymph node dissection [RPLND], or postchemotherapy). The correlation between ctDNA status and event-free survival (EFS) was assessed. RESULTS ctDNA testing was performed for 74 patients (324 plasma samples) with clinical stages I to III GCTs. The median age was 34 years (IQR, 27-39), and the median follow-up was 17 months (IQR, 12-25). Disease management postorchiectomy included surveillance in 23% (17/74), RPLND in 7% (5/74), chemotherapy in 41% (30/74), and chemotherapy + RPLND in 29% (22/74) of patients. Preorchiectomy ctDNA was detectable in 14 of 15 patients. During the MRD (N = 42) and surveillance (N = 51) windows, patients who were ctDNA-positive versus ctDNA-negative showed a significantly inferior EFS during MRD (hazard ratio [HR], 5.11 [95% CI, 1.31 to 19.95]; P = .019) and surveillance windows (HR, 12.45 [95% CI, 4.32 to 35.85]; P < .0001). By contrast, elevated versus normal STM was not associated significantly with worse EFS (MRD: HR, 2.97 [95% CI, 0.68 to 13.05]; P = .149. surveillance: HR, 1.74 [95% CI, 0.75 to 4.02]; P = .194). CONCLUSION Tumor-informed ctDNA analysis shows promise for MRD detection in patients with GCTs. With further study, ctDNA monitoring may be useful in clinical decision making. Larger prospective trials are planned to establish clinical utility.